Multiple myeloma is a malignancy which accounts for 14% of all hematological malignancies and for nearly 2% of all cancers. Despite progress in understanding of the disease biology and improvement therapeutic options in the recent years, multiple myeloma remains an incurable disease. A long-lasting remission after donor lymphocyte infusion in patients with relapse disease after allogeneic stem cell transplantation, the cytotoxic effect of new immunomodulating agents such as thalidomide and lenalidomide as well as immunotherapy in vitro models strongly supported the efficacy of immunotherapy-based therapy. Further improvement in understanding of immunological interactions between myeloma cells and microenvironment as well as the development of vaccination strategies and cell therapy approaches will certainly improve the therapeutic armamentarium in the treatment of multiple myeloma. We invite the authors to submit original research and review articles which help to design new immunotherapy-based therapeutic options in treatment of multiple myeloma. Potential topics include, but are not limited to:

• Development and testing of immunotherapy in in vitro models mimicking multiple myeloma
• Immunotherapy-based approaches targeting microenvironment and the neoplastic niche of multiple myeloma
• Elucidating the role of the adoptive and innate immunsystem in controlling multiple myeloma
• Identification of new myeloma-specific targets for immunotherapy
• The role of genetically modified immunsystem to target multiple myeloma
• Potential role of monoclonal and polyclonal antibodies in the treatment of multiple myeloma
• Immunological-based therapies to target the neoplastic niche
• Elucidating the role of vaccination strategies

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/jir/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable:

Manuscript Due	Friday, 4 January 2012
First Round of Reviews	Friday, 29 April 2012
Publication Date	Friday, 29 July 2012

Lead Guest Editor

• Nicolaus Kröger, Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany

Guest Editors

• Mohamad Mohty, Department of Hematology, University of Nantes, Nantes, France
• Arnon Nagler, Department of Hematology and Stem Cell Transplantation, The Chaim Sheba Medical Center, Tel Hashomer, Israel
• Qing Yi, Department of Lymphoma/Myeloma and Division of Cancer Medicine, Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA